Unlocking the Mystery of ITCI's Stock Surge

Intra-Cellular Therapies stock is trading -17.3% below its average target price of $91.64 after marking a 10.0% during today's afternoon session. Analysts are giving the Mid-Cap Pharmaceutical company an average rating of buy and target prices ranging from $65.0 to $120.0 per share.

Intra-Cellular Therapies's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 5.0%. The stock's short ratio is 3.16. Since 2.32% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests.

Another number to watch is the company's rate of institutional share ownership, which now stands at 89.7%. In conclusion, we believe there is mixed market sentiment regarding Intra-Cellular Therapies.

Institutions Invested in Intra-Cellular Therapies

Date Reported Holder Percentage Shares Value
2024-03-31 FMR, LLC 11% 11,194,613 $848,439,729
2024-03-31 Vanguard Group Inc 9% 9,225,981 $699,237,108
2024-03-31 Blackrock Inc. 8% 8,077,758 $612,213,286
2024-03-31 Wasatch Advisors LP 4% 3,854,747 $292,151,278
2024-03-31 Bellevue Group AG 3% 2,819,482 $213,688,543
2024-03-31 Avoro Capital Advisors LLC 2% 2,475,000 $187,580,252
2024-03-31 State Street Corporation 2% 2,240,695 $169,822,276
2024-03-31 Geode Capital Management, LLC 2% 2,065,298 $156,528,937
2024-03-31 Invesco Ltd. 2% 2,072,981 $157,111,231
2024-03-31 JP Morgan Chase & Company 2% 1,755,948 $133,083,300
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.